Last reviewed · How we verify

Ticlopidine + Ginko biloba — Competitive Intelligence Brief

Ticlopidine + Ginko biloba (Ticlopidine + Ginko biloba) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antiplatelet. Area: Cardiovascular.

phase 3 antiplatelet P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticlopidine + Ginko biloba (Ticlopidine + Ginko biloba) — Samsung Medical Center. Ticlopidine inhibits platelet aggregation by irreversibly blocking ADP receptors on platelets, while Ginkgo biloba has antioxidant and anti-inflammatory properties.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ticlopidine + Ginko biloba TARGET Ticlopidine + Ginko biloba Samsung Medical Center phase 3 antiplatelet P2Y12 receptor
Active Comparator: Rivaroxaban+Clopidogrel Active Comparator: Rivaroxaban+Clopidogrel Chinese Academy of Medical Sciences, Fuwai Hospital marketed Anticoagulant + Antiplatelet combination Factor Xa; P2Y12 receptor
Vorapaxar, Aspirin, and Clopidogrel Vorapaxar, Aspirin, and Clopidogrel Inova Health Care Services marketed Antiplatelet agent combination PAR-1 (vorapaxar); Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel)
Double antiplatelet therapy Double antiplatelet therapy University Hospital, Bordeaux marketed Antiplatelet combination therapy Cyclooxygenase (COX) and P2Y12 receptor
Acetylsalicylic Acid + clopidogrel + acenocoumarol Acetylsalicylic Acid + clopidogrel + acenocoumarol Hospital Universitari Vall d'Hebron Research Institute marketed Antiplatelet agent + Anticoagulant combination Platelet cyclooxygenase (COX), P2Y12 receptor, Vitamin K-dependent clotting factors
ticagrelor + ASA ticagrelor + ASA Peking University Third Hospital marketed Dual antiplatelet agent P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
Dabigatran + clopidogrel Dabigatran + clopidogrel Zuyderland Medisch Centrum marketed Anticoagulant + antiplatelet agent combination Thrombin (Factor IIa) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antiplatelet class)

  1. Beijing Tiantan Hospital · 1 drug in this class
  2. Catholic University of the Sacred Heart · 1 drug in this class
  3. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  4. NYU Langone Health · 1 drug in this class
  5. Samsung Medical Center · 1 drug in this class
  6. Sheba Medical Center · 1 drug in this class
  7. Sichuan Provincial People's Hospital · 1 drug in this class
  8. University of Athens · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticlopidine + Ginko biloba — Competitive Intelligence Brief. https://druglandscape.com/ci/ticlopidine-ginko-biloba. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: